COVID-19 therapeutics
Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …
has been studied and deployed. Healthcare providers have multiple treatment approaches …
Reversible Covalent Inhibition─ Desired Covalent Adduct Formation by Mass Action
Covalent inhibition has seen a resurgence in the last several years. Although long-plagued
by concerns of off-target effects due to nonspecific reactions leading to covalent adducts …
by concerns of off-target effects due to nonspecific reactions leading to covalent adducts …
High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients
S Huygens, A Gharbharan, Y Serroukh… - Journal of …, 2023 - academic.oup.com
Objectives Immunocompromised patients have an increased risk of severe or prolonged
COVID-19. Currently available drugs are registered to treat COVID-19 during the first 5 to 7 …
COVID-19. Currently available drugs are registered to treat COVID-19 during the first 5 to 7 …
[HTML][HTML] Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase …
Y Zhan, Z Lin, J Liang, R Sun, Y Li, B Lin, F Ge… - …, 2024 - thelancet.com
Background Leritrelvir is a novel α-ketoamide based peptidomimetic inhibitor of SARS-CoV-
2 main protease. A preclinical study has demonstrated leritrelvir poses similar antiviral …
2 main protease. A preclinical study has demonstrated leritrelvir poses similar antiviral …
Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens
I Ullah, F Escudie, I Scandale, Z Gilani… - Iscience, 2024 - cell.com
Direct acting antivirals (DAAs) represent critical tools for combating severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that have escaped …
syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that have escaped …
SARS-CoV-2 rebound with and without antivirals
N Petrosillo - The Lancet Infectious Diseases, 2023 - thelancet.com
As the COVID-19 pandemic continues, interventions for preventing SARS-CoV-2
transmission and progression to severe disease remain priorities. Vaccines against COVID …
transmission and progression to severe disease remain priorities. Vaccines against COVID …
Prevention and treatment strategies for kidney transplant recipients in the context of long-term existence of COVID-19
Z Zheng, H Sun, X Hu, Z Xuan, M Fu, Y Bai, Y Du… - Frontiers in …, 2024 - frontiersin.org
The sudden outbreak of coronavirus disease 2019 (COVID-19) in early 2020 posed a
massive threat to human life and caused an economic upheaval worldwide. Kidney …
massive threat to human life and caused an economic upheaval worldwide. Kidney …
Xuanfei Formula inhibited RSV infection by normalizing the SREBP2-mediated cholesterol synthesis process
H Qin, J Luo, N Zhao, W Lou, P Chen, H Wang… - Frontiers in …, 2024 - frontiersin.org
Background and aims Respiratory syncytial virus (RSV) is the major cause of lower
respiratory tract infections in children and the elderly, often progressing to pneumonia and …
respiratory tract infections in children and the elderly, often progressing to pneumonia and …
Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 …
P Pagliano, A Spera, C Sellitto, G Scarpati… - Expert Opinion on …, 2023 - Taylor & Francis
ABSTRACT Introduction Nirmatrelvir/ritonavir (Paxlovid®) represent an oral antiviral therapy
approved for the treatment of COVID-19. Extensive in vitro and in vivo studies have reported …
approved for the treatment of COVID-19. Extensive in vitro and in vivo studies have reported …
The Design, Synthesis and Mechanism of Action of Paxlovid, a Protease Inhibitor Drug Combination for the Treatment of COVID-19
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), has presented an enormous challenge to health care systems and medicine …
(SARS-CoV-2), has presented an enormous challenge to health care systems and medicine …